Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma
Kite beats BMS’s Breyanzi to the first CAR-T approval in second-line large B-cell lymphoma. The added indication could nearly double the number of potential US patients for Yescarta.
You may also be interested in...
With its HIV portfolio benefitting from a post-pandemic recovery, the drug maker said demand for Biktarvy drove higher US and Europe sales, while oncology products saw growth of 79% year-over-year.
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.